ANI Pharmaceuticals Inc (ANIP)vsUnited Therapeutics Corporation (UTHR)
ANIP
ANI Pharmaceuticals Inc
$70.19
-1.78%
HEALTHCARE · Cap: $1.64B
UTHR
United Therapeutics Corporation
$497.11
-1.34%
HEALTHCARE · Cap: $21.36B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 222% more annual revenue ($3.15B vs $978.38M). UTHR leads profitability with a 41.6% profit margin vs 11.1%. ANIP appears more attractively valued with a PEG of 1.06. ANIP earns a higher WallStSmart Score of 76/100 (B+).
ANIP
Strong Buy76
out of 100
Grade: B+
UTHR
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ANIP.
Margin of Safety
+0.8%
Fair Value
$479.95
Current Price
$497.11
$17.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 191.1% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 25.9% year-over-year
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 42.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Attractively priced relative to earnings
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ANIP
The strongest argument for ANIP centers on EPS Growth, P/E Ratio, Price/Book. Revenue growth of 25.9% demonstrates continued momentum. PEG of 1.06 suggests the stock is reasonably priced for its growth.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.
Bear Case : ANIP
The primary concerns for ANIP are Altman Z-Score, Market Cap.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
ANIP profiles as a growth stock while UTHR is a declining play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.56 — expect wider price swings.
ANIP is growing revenue faster at 25.9% — sustainability is the question.
UTHR generates stronger free cash flow (206M), providing more financial flexibility.
Bottom Line
ANIP scores higher overall (76/100 vs 61/100) and 25.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ANI Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?